New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas

Current Oncology

Aurélie Verney¹  Hervé Ghesquières¹  Emmanuel Bachy¹  Juliette Fontaine²  Marie Donzel²  Florian Pesce²  Alexandra Traverse-Glehen²  Lucile Baseggio³ 

[1] INSERM-Unité Mixte de Recherche 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, UCBL, Cancer Research Center of Lyon, Université Lyon, 69001 Lyon, France;Institut de pathologie multi-sites, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France;Laboratoire d’hématologie, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France;

关键词: splenic marginal zone lymphoma;    review;    genetic;    molecular;   

DOI  :  10.3390/curroncol28050297

来源: DOAJ

【 摘 要 】

Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been recognized as a distinct pathological entity since the WHO 2008 classification. It classically presents an indolent evolution, but a third of patients progress rapidly and require aggressive treatments, such as immuno-chemotherapy or splenectomy, with all associated side effects. In recent years, advances in the comprehension of SMZL physiopathology have multiplied, thanks to the arrival of new devices in the panel of available molecular biology techniques, allowing the discovery of new molecular findings. In the era of targeted therapies, an update of current knowledge is needed to guide future researches, such as those on epigenetic modifications or the microenvironment of these lymphomas.

【 授权许可】

Unknown